Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Bevacizumab, Gemcitabine + IMRT in Cisplatin-Ineligible Advanced NPC
NCT06364826Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Event-free survival rate at 3 years. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06364826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364826.